Get 50% OFF This Summer!
Balaxi Pharmaceuticals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Balaxi Ventures Limited (erstwhile known as The Anandam Rubber Company Limited) is a public limited company incorporated in India in September 28, 1942 with a basic objective of running rubber and tea plantations and owns several plantations across South India. In the year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products
Securities and Exchange Board of India (SEBI) vide Circular dated May 30, 2012 had issued revised Exit Policy for de-recognized/non-operational stock exchanges. Pursuant to the circular, Madras Stock Exchange has been de-recognized by SEBI, recently. Further, as per above cited circular issued by SEBI on May 30, 2012, and Public Notice issued by Madras Stock Exchange Limited (MSE), it cleared that the Exclusively Listed Companies, which fail to obtain listing on any other stock exchange, will cease to be a listed company and will be moved to the Dissemination Board by the exiting stock exchange. Also, it is to be noted that SEBI has given a time limit of eighteen months for getting listed with any of the recognized stock exchanges. In pursuance to the above notice, the company has submitted listing application with National Stock Exchange of India (NSE) Limited on 19th January 2015 under listing criteria for Exclusively Listed Companies. The submitted listing application is under process with the National Stock Exchange of India (NSE) Limited and the company is hoping to be get listed very soon. Madras Stock Exchange has intimated the Company that it has been placed before Dissemination Board (DB) of National Stock Exchange of India (NSE) Limited. Under the Dissemination Board mechanism, a willing buyer and seller will be given an opportunity to disseminate their offers using the services of brokers of stock exchanges hosting Dissemination Board.
On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).
The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' through Postal Ballot passed on August 08, 2017. It had also changed the Registered Office from 41/298 - D2, 2nd Floor, Saniya Plaza, Mahakavi Bharathiyar Road, Near KSRTC Bus Stand, Cochin - 682035 to Plot No.409, H.No. 8-2-293, MAPS Towers, 3rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad, Telangana, India -500096 through Postal Ballot passed on August 08, 2017.
The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders' hardware by way of a Postal Ballot passed on August 08, 2018. The Company commenced the business of international wholesale trading in pharmaceuticals and builders' hardware products starting September 2018. Further, in February 2019, The Company decided to kickstart its Food Products business by launching a range of biscuits under the brand YAP'.
The Board of the company approved the proposed preferential issue of 69,60,000 Equity shares on June 19, 2019 and subsequently obtained shareholder's approval on July 12, 2019 via Extra Ordinary General Meeting. The Company had obtained required approvals from stock exchange and allotted 69,60,000 Equity shares on preferential basis on August 09, 2019. Consequently, the Paid up share capital of the company has been accordingly increased from Rs 3,04,00,000/- consisting of 30,40,000 Equity shares of Rs 10/- each to Rs 10,00,00,000/- consisting of 1,00,00,000 Equity shares of Rs 10/- each.
Balaxi Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Balaxi Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Balaxi Pharmaceuticals is valued compared to its competitors.
Balaxi Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Balaxi Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Balaxi Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Balaxi Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Balaxi Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Balaxi Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Balaxi Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Balaxi Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Balaxi Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Balaxi Pharmaceuticals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Balaxi Pharmaceuticals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Balaxi Pharmaceuticals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Balaxi Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Balaxi Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Balaxi Pharmaceuticals .
The balance sheet presents a snapshot of Balaxi Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App